This Program Project Grant involves investigators from the University of Southern California participating in a multi disciplinary and highly interactive research effort on the development of gene therapy approaches for the treatment of cancer. The investigators are drawn from both basic science and clinical departments. Similarly, the projects reflect a central theme of using the basic disciplines of molecular biology, molecular genetics, cell biology and human genetics to bridge the gaps in our knowledge and use cellular transduction for clinical treatment. The Program consists of five research Projects and three Core resources. In Project l Dr. Parkman and colleagues will use retroviral vectors to mark positively selected hematopoietic stem cells in order to follow patients with Acute Lymphocytic Leukemia and to transduce such cells with the human multiple drug resistance gene for delivery to patients undergoing autologous bone marrow transplantation. In Project 2, Dr. Kedes and colleagues will develop transcriptionally active DNA vectors to genetically engineer and implant rodent myoblasts in order to deliver, both locally and systemically, a variety of antineoplastic polypeptides in animal tumor models. In Project 3 Dr. Donald Kohn and colleagues will define the role of DNA methylation in vector silencing and the ability of novel vectors to achieve persistent expression. In Project 4, Dr. Gunther Dennert and colleagues will test the ability of the glucose regulated protein gene promoter to drive the expression of cytokines in tumors in order to asses the role of these proteins in stimulating cell mediated immunity to transplanted tumors. In Project 5, Dr. W. French Anderson and colleagues will design chimeric retroviral envelope proteins to replace the natural coat proteins in an attempt to develop cell-type specific gene therapy delivery vehicles. The three Core resources include administration, viral vector development and animal models and these are integrated and interdependent. Finally, the Program is integrated in the University research community and in particular with the USC Gene Therapy Program which is a partnership between the Norris Comprehensive Cancer Center/Institute for Genetic Medicine Joint Gene Therapy Program and the Gene Therapy Programs of the Childrens Hospital Los Angeles.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Xie, Heng
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Internal Medicine/Medicine
Schools of Medicine
Los Angeles
United States
Zip Code
Perez, Omar D; Logg, Christopher R; Hiraoka, Kei et al. (2012) Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 20:1689-98
Christodoulopoulos, Ilias; Droniou-Bonzom, Magali E; Oldenburg, Jill E et al. (2010) Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology 7:4
Epand, Raquel F; Zhang, Yan-Liang; Mirzabekov, Tajib et al. (2008) Membrane activity of an amphiphilic alpha-helical membrane-proximal cytoplasmic domain of the MoMuLV envelope glycoprotein. Exp Mol Pathol 84:9-17
Rozenberg-Adler, Yanina; Conner, John; Aguilar-Carreno, Hector et al. (2008) Membrane-proximal cytoplasmic domain of Moloney murine leukemia virus envelope tail facilitates fusion. Exp Mol Pathol 84:18-30
Logg, Christopher R; Baranick, Brian T; Lemp, Nathan A et al. (2007) Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. J Mol Biol 369:1214-29
Hiraoka, Kei; Kimura, Takahiro; Logg, Christopher R et al. (2007) Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 67:5345-53
Weber, Erin L; Cannon, Paula M (2007) Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther 18:849-60
Kikuchi, Eiji; Menendez, Silvia; Ozu, Choichiro et al. (2007) Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Clin Cancer Res 13:4511-8
Hsu, Faye Yuan-yi; Zhao, Yi; Anderson, W French et al. (2007) Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest 25:240-8
Kikuchi, E; Menendez, S; Ozu, C et al. (2007) Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 14:279-86

Showing the most recent 10 out of 70 publications